Radiotherapy is Superior to Transarterial Chemoembolization As Adjuvant Therapy After Narrow-margin Hepatectomy in Patients with Hepatocellular Carcinoma: A Single-center Prospective Randomized Study

Overview

Journal Langenbecks Arch Surg

Specialty General Surgery

Date 2024 Mar 15

PMID 38488934

Authors

Tao Bai

Zhi-Hong Tang

Xiao-Bo Wang

Jie Chen

Jia-Zhou Ye

Shao-Long Lu

Meng Wei

Fei-Xiang Wu

Le-Qun Li

Affiliations

Soon will be listed here.

Abstract

Background: This study was recruited to compare the efficacy and safety of radiotherapy (RT) and transarterial chemoembolization (TACE) as postoperative adjuvant therapy after narrow-margin hepatectomy in hepatocellular carcinoma (HCC) patients.

Methods: This single-center prospective randomized study was conducted in the Cancer Hospital, Guang Xi Medical University, Nanning. A total of 72 patients who received treatment in this hospital between August 2017 and July 2019 were included and randomly allocated to TACE group (n = 48) and RT group (n = 24). Next, overall survival (OS) and progression-free survival (PFS) rates, recurrence patterns, financial burden, and safety were evaluated.

Results: The difference between the RT and TACE groups was not significant in one-, three-, and five-year OS (87.5%, 79.0%, and 62.5% vs. 93.8%, 75.9%, and 63.4%, respectively, P = 0.071) and PFS rates (79.0%, 54.2%, and 22.6% vs. 75.0%, 47.9%, and 32.6%, respectively, P = 0.071). Compared to the TACE group, the RT group had significantly lower intrahepatic recurrence rate (20.8% vs. 52.1%, P = 0.011), higher extrahepatic recurrence rate (37.5% vs. 14.6%, P = 0.034), and no marginal and diffuse recurrences (0% vs. 16.7%, P < 0.05). The mean overall treatment cost was higher (¥62,550.59 ± 4397.27 vs. ¥40,732.56 ± 9210.54, P < 0.01), the hospital stay (15.1 ± 3.7 vs. 11.8 ± 4.1 days, P < 0.01) was longer, and the overall treatment stay (13.3 ± 5.3 vs. 41.29 ± 12.4 days, P < 0.01) was shorter in the TACE group than in the RT group. Besides, both groups did not exhibit significant differences in the frequency and severity of adverse events.

Conclusion: Both adjuvant TACE and RT can better the OS and PFS of patients with HCC. However, RT has a significantly better performance than TACE in terms of improving intrahepatic recurrence rate, treatment cost and hospital stay.

References

Feng R, Su Q, Huang X, Basnet T, Xu X, Ye W . Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration?. Cancer Commun (Lond). 2022; 43(1):75-86. PMC: 9859730. DOI: 10.1002/cac2.12393. View

Torimura T, Iwamoto H . Treatment and the prognosis of hepatocellular carcinoma in Asia. Liver Int. 2021; 42(9):2042-2054. DOI: 10.1111/liv.15130. View

Goh B, Chua D, Koh Y, Tan E, Kam J, Teo J . Continuous improvements in short and long-term outcomes after partial hepatectomy for hepatocellular carcinoma in the 21st century: Single institution experience with 1300 resections over 18 years. Surg Oncol. 2021; 38:101609. DOI: 10.1016/j.suronc.2021.101609. View

Bruix J, Takayama T, Mazzaferro V, Chau G, Yang J, Kudo M . Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015; 16(13):1344-54. DOI: 10.1016/S1470-2045(15)00198-9. View

Shi C, Li Y, Geng L, Shen W, Sui C, Dai B . Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial. Eur J Cancer. 2022; 166:176-184. DOI: 10.1016/j.ejca.2022.02.012. View

Yang J, Liang H, Hu K, Xiong Z, Cao M, Zhong Z . The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis. Cancer Cell Int. 2021; 21(1):92. PMC: 7868028. DOI: 10.1186/s12935-021-01790-6. View

Akateh C, Black S, Conteh L, Miller E, Noonan A, Elliott E . Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol. 2019; 25(28):3704-3721. PMC: 6676544. DOI: 10.3748/wjg.v25.i28.3704. View

Chen L, Martinelli E, Cheng A, Pentheroudakis G, Qin S, Bhattacharyya G . Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020; 31(3):334-351. DOI: 10.1016/j.annonc.2019.12.001. View

Miao X, Hu J, Dai W, Zhong D, Xiong S . Null-margin mesohepatectomy for centrally located hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology. 2011; 58(106):575-82. View

10.

Nara S, Shimada K, Sakamoto Y, Esaki M, Kishi Y, Kosuge T . Prognostic impact of marginal resection for patients with solitary hepatocellular carcinoma: evidence from 570 hepatectomies. Surgery. 2012; 151(4):526-36. DOI: 10.1016/j.surg.2011.12.002. View

11.

Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y . Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer. 2004; 101(4):796-802. DOI: 10.1002/cncr.20426. View

12.

Liu L, Shui Y, Yu Q, Guo Y, Zhang L, Zhou X . Narrow-Margin Hepatectomy Resulted in Higher Recurrence and Lower Overall Survival for R0 Resection Hepatocellular Carcinoma. Front Oncol. 2021; 10:610636. PMC: 7859433. DOI: 10.3389/fonc.2020.610636. View

13.

Chen B, Wu J, Cheng S, Wang L, Rong W, Wu F . Phase 2 Study of Adjuvant Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC. Hepatology. 2021; 74(5):2595-2604. PMC: 8672362. DOI: 10.1002/hep.31993. View

14.

Gou X, Shi H, Li C, Chen Z, Ouyang W, Sun L . Association of Adjuvant Radiation Therapy With Long-Term Overall and Recurrence-Free Survival After Hepatectomy for Hepatocellular Carcinoma: A Multicenter Propensity-Matched Study. Int J Radiat Oncol Biol Phys. 2022; 114(2):238-249. DOI: 10.1016/j.ijrobp.2022.05.020. View

15.

Wang W, Wang Z, Wu J, Zhang T, Rong W, Wang L . Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels. Liver Int. 2015; 35(12):2603-10. DOI: 10.1111/liv.12857. View

16.

Wang L, Qiu L, Ke Q, Ji H, Wu J . Systematic review of adjuvant external beam radiotherapy for hepatocellular carcinoma following radical hepatectomy. Radiother Oncol. 2022; 175:101-111. DOI: 10.1016/j.radonc.2022.08.019. View

17.

Wang Z, Ren Z, Chen Y, Hu J, Yang G, Yu L . Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study. Clin Cancer Res. 2018; 24(9):2074-2081. DOI: 10.1158/1078-0432.CCR-17-2899. View

18.

Wei W, Jian P, Li S, Guo Z, Zhang Y, Ling Y . Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun (Lond). 2018; 38(1):61. PMC: 6235393. DOI: 10.1186/s40880-018-0331-y. View

19.

Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J . Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002; 95(9):1931-7. DOI: 10.1002/cncr.10892. View

20.

Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A . BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2021; 76(3):681-693. PMC: 8866082. DOI: 10.1016/j.jhep.2021.11.018. View